Literature DB >> 22820893

Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.

Sazan Rasul1, Ludwig Wagner, Alexandra Kautzky-Willer.   

Abstract

Although type 2 diabetes mellitus (DM) is a chronic metabolic disorder with multiple etiologies, obesity has been constantly linked with insulin resistance and manifestation of type 2 DM. In addition, obesity is associated with hypertension, dyslipidemia, and fatty liver disease and is regarded as a subclinical inflammatory condition characterized by release of pro-inflammatory mediators such as cytokines from adipose tissue. Both, type 2 DM and obesity are considered as major risks for developing micro- and macrovascular diseases. Recent studies showed that impaired circulating levels of fetuin-A, which is involved in propagating insulin resistance as well as circulating levels of angiopoietins, which are growth factors promoting angiogenesis, were observed in patients with obesity, metabolic syndrome, and type 2 DM. However, independent of type 2 DM and obesity, defective regulation of fetuin-A and angiopoietin are playing a critical role in predisposing to coronary and peripheral vascular diseases. Therefore, mechanisms linking type 2 DM and obesity with fetuin-A and angiopoietins seem to be complex and are in need of further exploration. In this review, we aimed to present a summary concerning associations of type 2 diabetes, obesity, and vascular diseases with circulating levels of angiopoietins and fetuin-A. Furthermore, we aimed to focus on roles of fetuin-A and angiopoietins and to highlight the most plausible mechanisms that might explain their associations with type 2 DM and obesity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820893     DOI: 10.1007/s12020-012-9754-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  122 in total

1.  High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A.

Authors:  Dachun Yao; Tetsuya Taguchi; Takeshi Matsumura; Richard Pestell; Diane Edelstein; Ida Giardino; Guntram Suske; Naila Rabbani; Paul J Thornalley; Vijay P Sarthy; Hans-Peter Hammes; Michael Brownlee
Journal:  J Biol Chem       Date:  2007-08-01       Impact factor: 5.157

2.  Fetuin-null mice are protected against obesity and insulin resistance associated with aging.

Authors:  Suresh T Mathews; Sanjay Rakhade; Xiaohua Zhou; Graham C Parker; Donald V Coscina; George Grunberger
Journal:  Biochem Biophys Res Commun       Date:  2006-09-25       Impact factor: 3.575

3.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss.

Authors:  Johanna Maria Brix; Harald Stingl; Florian Höllerl; Gerit Holger Schernthaner; Hans-Peter Kopp; Guntram Schernthaner
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

5.  Adipose tissue mass can be regulated through the vasculature.

Authors:  Maria A Rupnick; Dipak Panigrahy; Chen-Yu Zhang; Susan M Dallabrida; Bradford B Lowell; Robert Langer; M Judah Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

6.  AHSG gene variation is not associated with regional body fat distribution--a magnetic resonance study.

Authors:  K Müssig; H Staiger; F Machicao; J Machann; A M Hennige; F Schick; C D Claussen; A Fritsche; H-U Häring; N Stefan
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-04-08       Impact factor: 2.949

7.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

Authors:  Philip A Kern; Gina B Di Gregorio; Tong Lu; Negah Rassouli; Gouri Ranganathan
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

Review 8.  Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?

Authors:  Amaia Rodríguez; Victoria Catalán; Javier Gómez-Ambrosi; Gema Frühbeck
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

10.  Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study.

Authors:  Sazan Rasul; Marie Helene Reiter; Aysegul Ilhan; Katharina Lampichler; Ludwig Wagner; Alexandra Kautzky-Willer
Journal:  Cardiovasc Diabetol       Date:  2011-06-23       Impact factor: 9.951

View more
  15 in total

1.  Comparison of high-sensitivity C-reactive protein and fetuin-A levels before and after treatment for subjects with subclinical hyperthyroidism.

Authors:  Oktay Bilgir; Ferda Bilgir; Tuba Topcuoglu; Mehmet Calan; Ozlem Calan
Journal:  Endocrine       Date:  2013-06-19       Impact factor: 3.633

2.  A preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging.

Authors:  Fabian Sanchis-Gomar; Helios Pareja-Galeano; Alejandro Santos-Lozano; Nuria Garatachea; Carmen Fiuza-Luces; Letizia Venturini; Giovanni Ricevuti; Alejandro Lucia; Enzo Emanuele
Journal:  Age (Dordr)       Date:  2015-04-25

3.  Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus.

Authors:  Liang Yin; Wei-Juan Cai; Ling-Yun Zhu; Jun Li; Xiang-Hui Su; Xiao-Li Wang; Xiang-Yun Chang; Kan Sun
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Effects of sleeve gastrectomy and rs9930506 FTO variants on angiopoietin/Tie-2 system in fat expansion and M1 macrophages recruitment in morbidly obese subjects.

Authors:  Nicté Figueroa-Vega; Benjamín Jordán; Elva Leticia Pérez-Luque; Luis Parra-Laporte; Serafín Garnelo; Juan Manuel Malacara
Journal:  Endocrine       Date:  2016-08-31       Impact factor: 3.633

5.  Association between fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus.

Authors:  Liang Yin; Wei-Juan Cai; Xiang-Yun Chang; Jun Li; Xiang-Hui Su; Ling-Yun Zhu; Xiao-Li Wang; Kan Sun
Journal:  Biomed Rep       Date:  2014-09-05

Review 6.  Fetuin-A: a novel link between obesity and related complications.

Authors:  J F Trepanowski; J Mey; K A Varady
Journal:  Int J Obes (Lond)       Date:  2014-12-03       Impact factor: 5.095

7.  Causal relationship between the AHSG gene and BMD through fetuin-A and BMI: multiple mediation analysis.

Authors:  C Sritara; A Thakkinstian; B Ongphiphadhanakul; L Chailurkit; S Chanprasertyothin; W Ratanachaiwong; P Vathesatogkit; P Sritara
Journal:  Osteoporos Int       Date:  2014-02-26       Impact factor: 4.507

8.  Association between alcohol consumption and plasma fetuin-A and its contribution to incident type 2 diabetes in women.

Authors:  Sylvia H Ley; Qi Sun; Monik C Jimenez; Kathryn M Rexrode; Joann E Manson; Majken K Jensen; Eric B Rimm; Frank B Hu
Journal:  Diabetologia       Date:  2013-10-09       Impact factor: 10.122

9.  Fetuin-A (α2HS-glycoprotein) is a serum chemo-attractant that also promotes invasion of tumor cells through Matrigel.

Authors:  Gladys N Nangami; Kurt Watson; Kitani Parker-Johnson; Kelechi O Okereke; Amos Sakwe; Pamela Thompson; Nanna Frimpong; Josiah Ochieng
Journal:  Biochem Biophys Res Commun       Date:  2013-08-07       Impact factor: 3.575

10.  Relationship of vitamin D status and bone mass according to vitamin D-binding protein genotypes.

Authors:  Hataikarn Nimitphong; Chanika Sritara; La-Or Chailurkit; Suwannee Chanprasertyothin; Wipa Ratanachaiwong; Piyamitr Sritara; Boonsong Ongphiphadhanakul
Journal:  Nutr J       Date:  2015-03-24       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.